PDL BioPharma, Inc. (PDLI) Reports In-Line Q4 EPS

PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q4 EPS of $0.24, in-line with the analyst estimate of $0.24. Revenue for the quarter came in at $72.81 million versus the consensus estimate of $72.85 million.

For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c
• Aptera Motors (SEV) Reports Q2 Loss of $0.20